Mangalam Drugs & Organics Ltd

MANGALAM

Company Profile

  • Business description

    Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.

  • Contact

    P. D'Mello Road
    Rupam Building, 3rd Floor, No. 239
    Near General Post Office
    MumbaiMH400001
    IND

    T: +91 2222616200

    https://www.mangalamdrugs.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2027

    Employees

    480

Stocks News & Analysis

stocks

Eli Lilly receives FDA approval to add another oral GLP-1 to market

Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Which of the 3 giant AI IPOs should you buy?

OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,774.90124.80-1.40%
CAC 407,962.390.000.00%
DAX 4023,168.08130.81-0.56%
Dow JONES (US)46,504.6761.07-0.13%
FTSE 10010,436.2971.500.69%
HKSE25,116.53177.50-0.70%
NASDAQ21,879.1838.230.18%
Nikkei 22553,123.49660.221.26%
NZX 50 Index12,902.1576.280.59%
S&P 5006,582.697.370.11%
S&P/ASX 2008,579.50105.50-1.21%
SSE Composite Index3,919.2929.27-0.74%

Market Movers